Burn News and Research

RSS

NovaBay second-quarter net loss increases to $1.2 million

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, today reported second quarter financial results and highlighted the clinical progress of its in-house programs.

13 Aug 2010

ARMC completes system-wide conversion to Masimo rainbow technology

Arrowhead Regional Medical Center (ARMC) in Colton, California, and Masimo, the inventor of Masimo rainbow Pulse CO-Oximetry, Masimo rainbow Acoustic Monitorin, and Masimo SET Measure-Through Motion and Low Perfusion pulse oximetry, today jointly announced the completion of ARMC's system-wide conversion to Masimo rainbow technology.

13 Aug 2010

Antares Pharma second-quarter total revenue increases 78% to $3.1 million

Antares Pharma, Inc. today reported financial and operating results for the second quarter ended June 30, 2010.

13 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Loyola University forms new institute for molecular level disease research

Loyola University Chicago Stritch School of Medicine has formed a new research institute dedicated to understanding the molecular causes of cancer, autoimmune disorders, cardiovascular disease and several other illnesses.

10 Aug 2010

Bellus Health reports net loss of $5.8M for second-quarter vs. net income of $14.27M for previous year

BELLUS Health Inc. reported today its financial results for the second quarter ended June 30, 2010. The Company also announced new initiatives to reduce its annual expenditures ("burn rate") by focusing its efforts on existing products and on supporting current and future strategic partnerships. All currency figures reported in this press release, including comparative figures, are in Canadian dollars, unless otherwise specified.

9 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Opexa Therapeutics aims to complete planned experiments, develop clinical study protocols

Opexa Therapeutics, Inc., a company developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended June 30, 2010 and provided an update on its corporate developments.

7 Aug 2010

Halozyme second-quarter revenue increases to $3.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the second quarter ended June 30, 2010.

7 Aug 2010

GenVec reports net loss of $4.2M for second-quarter 2010

GenVec, Inc. today announced its financial results for the second quarter ended June 30, 2010.

6 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

New laboratory to speed up research for melanoma treatment set up at University of Bristol

A new Skin Cancer Research Fund Laboratory has been set up in Bristol to study cancer cells collected from skin cancer patients attending Frenchay Hospital. It is hoped the new facility will speed up research into treatments for malignant melanoma - the most deadly form of skin cancer. The new laboratory at the Microvascular Research Laboratories at the University of Bristol will be officially opened today (Tuesday August 22nd) by the director of the Skin Cancer Research Fund, Mr Paul Townsend.

6 Aug 2010

BioCryst second-quarter total revenues increase to $7.6 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Discovery Laboratories reports net loss of $6.3 million for second-quarter 2010

Discovery Laboratories, Inc., a biotechnology company developing its novel, synthetic, peptide-containing surfactant and related aerosolization technologies as first in class therapies for severe respiratory diseases, today provides an update on key pipeline and business initiatives and reports financial results for the second quarter ended June 30, 2010.

4 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Access Pharmaceuticals initiates Phase I/II dose escalating study for Thiarabine

Access Pharmaceuticals, Inc., today announced it has initiated a Phase I/II dose-escalating study of its proprietary, anti-cancer drug, Thiarabine, a nucleoside analog for patients with hematologic malignancies (cancers of the blood). The primary objective of the study is to determine the maximum tolerated dose (MTD) in two different dosing schedules with various leukemias and lymphomas and recommended Phase II dose. The program is being led by Hagop Kantarjian, M.D., Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas.

4 Aug 2010

Tips to tackle dental emergency situations

Minneapolis Dental Emergency - Having to deal with a dental emergency is not something people think about. However, being prepared can make the difference between saving or losing a tooth. And in the case of a toothache, if it involves a bacterial infection, it can be a life-threatening situation.

29 Jul 2010

Adolor second-quarter net loss decreases to $8.3 million

Adolor Corporation today reported a net loss of $8.3 million, or $(0.18) per basic and diluted share, for the three months ended June 30, 2010, compared to a net loss of $16.5 million, or $(0.36) per basic and diluted share, for the three months ended June 30, 2009. For the six months ended June 30, 2010, Adolor reported a net loss of $17.9 million, or $(0.39) per basic and diluted share, compared to a net loss of $29.7 million, or $(0.64) per basic and diluted share, for the six months ended June 30, 2009.

29 Jul 2010

Antigenics second-quarter net loss attributable to common stockholders decreases to $5.2 million

Antigenics Inc. reported today its results for the quarter ended June 30, 2010.

29 Jul 2010

E-cigarette aerosol decreases over time in smoke-out interval, researchers find

Stronger suction is required to smoke "electronic cigarettes" - marketed as tobacco-free nicotine delivery systems - than conventional brands, with possible adverse effects on human health, researchers at the University of California, Riverside report.

29 Jul 2010